Welcome to our dedicated page for Avanos Medical news (Ticker: AVNS), a resource for investors and traders seeking the latest updates and insights on Avanos Medical stock.
Company Overview
Avanos Medical, Inc. (NYSE: AVNS) is a United States-based medical technology company that focuses on delivering clinically superior medical device solutions. With a clear commitment to addressing critical healthcare needs such as pain management, recovery, and digestive health, the company leverages breakthrough technologies that aid patients in returning to the activities that matter most. By integrating state-of-the-art innovation and robust patient-centric solutions, Avanos Medical stands as a noteworthy participant in the rapidly evolving field of medical device innovation.
Core Business Areas
At its core, Avanos Medical specializes in the development, manufacturing, and marketing of advanced therapeutic devices. The company has refined its commercial operations by combining its Chronic Care and Pain Management franchises into a structured commercial organization centered on two primary divisions:
- Digestive Health: This division emphasizes life-sustaining nutritional support by providing essential solutions such as neonatal and pediatric feeding systems. Products in this category are designed to offer enhanced safety and efficacy from hospital to home.
- Pain Management and Recovery: Focused on non-opioid therapeutic alternatives, this segment includes innovative cold compression systems and infusion devices that deliver precise pain management. These solutions are tailored to reduce opioid reliance while supporting patient recovery post-surgery and in chronic care settings.
Innovation and Transformation
Avanos Medical is undergoing a significant transformation designed to refine its product portfolio and enhance operational efficiency. This transformation involves:
- Investing in breakthrough technologies that improve clinical outcomes.
- Enhancing manufacturing processes to ensure high-quality standards.
- Streamlining operations by integrating product categories and reducing redundancies.
- Strengthening its competitive positioning by focusing on non-opioid therapies and recovery technologies.
The company’s focus on innovative design and efficient production is evident in its recent launch of advanced solutions such as improved feeding tube retention systems and state-of-the-art recovery technologies. These developments underscore Avanos Medical's commitment to clinical excellence and the continuous advancement of patient care solutions.
Global Market Position and Reach
Headquartered in Alpharetta, Georgia, Avanos Medical operates on a global scale, marketing its recognized brands across more than 90 countries. Its expansive distribution network and strong relationships with healthcare providers reinforce its position as a major player in the medical device industry. The company’s ability to adapt to different healthcare environments and regulatory requirements underlines its expertise and commitment to patient safety and quality of care.
Patient-Centric Solutions and Industry Impact
Avanos Medical’s solutions are engineered with the patient in mind. By targeting key healthcare challenges—such as reducing the use of opioids and enhancing recovery processes—the company not only meets clinical needs but also contributes to broader public health objectives. In an industry where treatment efficacy and patient safety are paramount, Avanos Medical’s focus on non-opioid pain management and innovative nutritional support provides clear benefits that resonate across healthcare settings.
Technological Capabilities and Product Portfolio
A significant aspect of Avanos Medical’s strategy involves integrating advanced technology into its product offerings. The company employs innovative systems such as cold compression therapy and combination modalities that merge traditional techniques with new technological advancements. These comprehensive solutions are designed to:
- Support recovery faster and more effectively.
- Ensure consistent and accurate delivery of treatment.
- Enhance clinical performance and patient safety.
This focus on technological integration not only highlights the company’s commitment to research and development but also reinforces its authoritative standing in an increasingly competitive market.
Operational Excellence and Strategic Transformation
The company continues to streamline its business operations under a clearly articulated transformation initiative. By consolidating product portfolios and focusing on its core segments, Avanos Medical aims to optimize operational performance while mitigating risks associated with market fluctuations. Emphasis on cost-management, disciplined spending, and transformational process improvements has been instrumental in securing its competitive edge.
Competitive Landscape
Within the broader medical device industry, Avanos Medical differentiates itself through:
- A focus on clinically validated, non-opioid treatment alternatives.
- Strong global brand recognition and extensive market reach.
- An evolving portfolio that addresses both immediate and long-term healthcare challenges.
The company’s strategic decision to concentrate on high-impact areas such as digestive health and pain management enables it to navigate competitive pressures while continuing to innovate.
Conclusion
In summary, Avanos Medical is a prominent medical technology company committed to delivering breakthrough solutions that address critical healthcare needs. From its patient-centric approach and innovative technological applications to its expansive global operations and focused transformation initiatives, the company demonstrates a robust operational framework and deep industry expertise. Whether through advanced pain management systems or essential nutritional support solutions, Avanos Medical’s offerings are designed to improve clinical outcomes and elevate the standard of patient care worldwide.
Avanos Medical (NYSE: AVNS) announced it will take direct control of sales and distribution for its MIC-KEY enteral feeding products in the United Kingdom starting July 25, 2025. This change ends a 29-year distribution partnership with Vygon UK, who has been distributing the MIC* and MIC-KEY product family.
The strategic transition aims to strengthen Avanos' direct relationship with healthcare professionals and patients, while ensuring product availability and customer support. MIC-KEY, a low-profile feeding tube system for enteral nutrition, is currently distributed in over 60 countries across six continents and has been trusted by clinicians and patients for over 25 years.
Avanos will provide guidance to healthcare providers currently purchasing through Vygon UK to ensure a smooth transition with minimal disruption to the ordering process.
Avanos Medical (NYSE: AVNS) has appointed David Pacitti as its new Chief Executive Officer, effective April 14, 2025. Pacitti joins from Siemens Medical Solutions USA, where he served as president and Head of the Americas for Siemens Healthineers, overseeing marketing, sales, service, and support functions across North and Latin America.
Pacitti brings extensive healthcare industry experience, including leadership roles at Abbott Vascular, where he served as division vice president of U.S. commercial operations and played key roles in launching the company's first drug-eluting stent franchise. His prior experience includes positions at Guidant Corp from 1995 to 2006.
Currently, Pacitti serves as chair of AdvaMed Medical Imaging Technology Division's board and holds board positions at Orchestra BioMed and the Siemens Foundation. He holds a bachelor's degree from Villanova University and an MBA from the University of Maryland.
Avanos Medical (NYSE: AVNS) reported its Q4 and full-year 2024 results, showing mixed performance. Q4 net sales reached $179.6 million, up 3.6% year-over-year, while full-year sales grew 2.2% to $687.8 million.
The company recorded a significant Q4 net loss of $397.0 million, largely due to a $436.7 million impairment charge on goodwill and intangible assets. Despite this, free cash flow improved to $82.9 million for 2024, compared to $14.6 million in 2023.
Q4 adjusted earnings per share increased to $0.43 from $0.36 year-over-year, while full-year adjusted EPS rose to $1.35 from $1.03. The company's net debt decreased to $27.0 million from $80.3 million previous year.
For 2025, Avanos projects net sales between $665-685 million and adjusted EPS of $1.05-1.25, reflecting challenging market conditions and currency headwinds.
Avanos Medical (NYSE: AVNS) has scheduled a conference call and webcast for Wednesday, Feb. 26 at 9 a.m. ET to discuss its fourth quarter and full year 2024 financial results. The company will release detailed financial results before the market opens on the same day. Michael Greiner, interim CEO, and Scott Galovan, senior vice president of strategy and corporate development, will host the call.
Participants can join the conference call through an automatic registration link or by dialing directly. A simultaneous webcast and related presentation will be available through the Investors section of the Avanos Medical website. The replay will be accessible for one week after the call.
Avanos Medical is a medical technology company based in Alpharetta, Georgia, focusing on medical device solutions for patient care, particularly in nutrition delivery and post-surgical recovery with reduced opioid use.
Avanos Medical (NYSE: AVNS) has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Michael Greiner, the company's interim chief executive officer, will deliver a presentation on Monday, January 13, at approximately 3:45 p.m. PST.
The presentation will be accessible via webcast through the Investors section of the Avanos Medical website, where it will also be archived for future reference.
Avanos Medical (NYSE: AVNS) has announced its participation in the Stifel 2024 Healthcare Conference. Michael Greiner, interim CEO, will engage in an analyst-led fireside chat at the Lotte New York Palace on Tuesday, Nov. 19 at 3:35 p.m. ET. The presentation will be accessible via webcast on the company's website's Investors section, where it will also be archived for future reference.
The Centers for Medicare and Medicaid Services (CMS) announced that Avanos Medical's ON-Q elastomeric infusion pump and ambIT disposable electronic infusion pump will receive separate Medicare payments under the NOPAIN Act starting January 1, 2025. This decision, part of the Medicare Hospital Outpatient Prospective Payment System (OPPS) and Medicare Ambulatory Surgical Center (ASC) Payment System rule for 2025, aims to enhance access to non-opioid pain management in HOPD and ASC settings. The NOPAIN Act, effective until December 31, 2027, provides additional Medicare reimbursement for qualifying non-opioid items to reduce opioid reliance. Both ON-Q and ambIT pumps will have unique HCPCS codes (C9804 and C9806) and a payment limit of up to $2,284.98 each. This move by CMS is a significant step in promoting safer pain management alternatives for Medicare beneficiaries.
Avanos Medical (NYSE: AVNS) has announced its participation in the UBS 2024 Healthcare Conference. Michael Greiner, the company's interim chief executive officer, will engage in a fireside chat on Tuesday, November 12 at approximately 2:45 p.m. Pacific Time. The presentation will be accessible via webcast through the Investors section of the Avanos Medical website, where it will also be archived for future reference.
Avanos Medical (NYSE: AVNS) has launched its new CORGRIP SR Nasogastric/Nasointestinal Tube Retention System, expanding its Enteral Feeding portfolio. The system features a monofilament thread and is designed to reduce feeding tube dislodgement, which occurs in 40%-63% of tape-secured tubes. Key features include a yellow-tipped retrieval catheter with hollow tip, color-coded clips, printed centimeter markings, and an orange opening tool. The nasal bridle solution aims to improve tube survival rates and reduce complications associated with tube replacement.
Avanos Medical (NYSE: AVNS) reported Q3 2024 financial results and announced CEO Joe Woody's retirement. Total net sales were $170.4 million, down 0.5% year-over-year. The company reported net income of $5.9 million, compared to a net loss of $8.8 million in the prior year. Adjusted EBITDA increased to $30.6 million from $27.8 million. Despite transformation progress, the company fell short of mid-single-digit organic growth targets. The company updated its 2024 outlook, expecting revenue between $683-688 million and adjusted diluted EPS of $1.30-1.35.
FAQ
What is the current stock price of Avanos Medical (AVNS)?
What is the market cap of Avanos Medical (AVNS)?
What does Avanos Medical do?
What are the core business areas of Avanos Medical?
How does Avanos Medical maintain its competitive edge in the industry?
What technologies or therapies is Avanos Medical known for?
In which markets does Avanos Medical operate?
How does Avanos Medical address patient safety and recovery?
What is the significance of the company’s transformation process?
How do Avanos Medical's products contribute to reducing opioid usage?
